Sepracor Reports Promising Phase III Data For Epilepsy Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Late 2008/early 2009 NDA filing is targeted for eslicarbazepine as adjunct therapy for epileptic seizure control.
You may also be interested in...
Sepracor Considers Partnering Late-stage Internal CNS Compounds
Progress not “gated” by partnering, but cost/risk sharing means speedier development, CEO says.
Sepracor Considers Partnering Late-stage Internal CNS Compounds
Progress not “gated” by partnering, but cost/risk sharing means speedier development, CEO says.
Sepracor Reports Positive Data From Lunesta Trial In Generalized Anxiety
Firm may be planning to expand the label for its insomnia drug.